Showing 1211-1220 of 5345 results for "".
- UCB Receives European Approval for Hidradenitis Suppurativa Treatment Bimzelxhttps://practicaldermatology.com/news/ucb-receives-european-approval-hidradenitis-suppurativa-treatment-bimzelx/2462815/The European Commission has granted marketing authorization for UCB’s Bimzelx (bimekizumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy.1 Bimzelx is the first IL-17A and IL-17F bi
- Study: Potential for Combined Laser Treating Vascular and Pigmented Lesionshttps://practicaldermatology.com/news/combined-laser-shows-potential-vascular-and-pigmented-lesions/2462743/A novel laser with cryogen cooling long-pulsed options of both 532nm and 1,064nm laser offers laser surgeons a safe and effective way to treat vascular and pigmented lesions with a single device and significantly different clinical endpoints, wrote Nicole M. Golbari, MD, of the University of Cali
- Cosmeceutical Market Continues Strong Rise, May Double by 2030https://practicaldermatology.com/news/cosmeceutical-market-continues-strong-rise-may-double-2030/2462662/Advances in technology, an aging population, and increasing interest in natural and organic products are among the trends driving growth in the global cosmeceutical market, according to data from a recent consumer report from SNS Insider, a market research company. The global cosmeceutica
- Analysis Highlights Factors Affecting Long-term Antibiotic Prescriptions for Acnehttps://practicaldermatology.com/news/analysis-highlights-factors-affecting-long-term-antibiotic-prescriptions-acne/2462633/A new analysis provided insight into the thinking of dermatologists prescribing antibiotics for treating acne. The research team set out to identify factors influencing prolonged oral antibiotic prescriptions for acne treatment by dermatologists, despite guidelines recommending limitation
- Updated Coding Curbs Complex Repair Billing by Mohs Surgeonshttps://practicaldermatology.com/news/updated-coding-curbs-complex-repair-billing-mohs-surgeons/2462489/Complex repairs billed by Mohs surgeons decreased significantly from 2019 to 2021 in the wake of new coding guidelines, according to a national Medicare analysis. Publishing in Dermatologic Surgery, Christian Gronbeck, MD, of the University of Connecticut, Farmington, and colleag
- Study Highlights Orofacial Anomalies in Kindler Epidermolysis Bullosahttps://practicaldermatology.com/news/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2462441/A new study in JAMA Dermatology suggests that hypoplastic pitted amelogenesis imperfecta is a feature of Kindler epidermolysis bullosa (KEB). "Kindler epidermolysis bullosa is a genetic skin-blistering disease associated with recessive inherited pathogenic varia
- Mediterranean Diet Adherence Not a Factor in Diagnosis or Severity of Acne: Studyhttps://practicaldermatology.com/news/mediterranian-diet-not-linked-with-acne-development-study/2462437/Results from a new analysis in the Journal of Health, Population, and Nutrition failed to show a link between adherence to a Mediterranean diet and an impact on acne severity or diagnosis. "Western diets, characterized by a high glycemic index and dairy content, can be risk fact
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- Study: Seborrheic Dermatitis Has Distinct Molecular Signaturehttps://practicaldermatology.com/news/study-seborrheic-dermatitis-has-distinct-molecular-signature/2462428/Newly unveiled research suggests that seborrheic dermatitis has its own unique molecular signature and is distinct in its own disease-specific pattern. “The pathophysiology of seborrheic dermatitis has been poorly understood. We sought to understand the gene expression patterns in seborrh